mRNA Vaccine in biopharma research laboratory

Vaccine Research Discovered

Well thought-out tools for pharmaceutical and biotech laboratories

THE MOST NOVEL VACCINES

Nucleic acid vaccines
Nucleic acid vaccines are made up of mRNA or plasmid DNA encoding viral antigenic components to express specific proteins of a pathogen after injection. The technology of mRNA vaccines made its breakthrough with SARS-CoV-2. With dozens of new applications including HIV, cancer, shingles, flu, cardiovascular applications, or Zika, it is a very promising technology.

➕ Multiple advantages such as exceptionally fast modifiability in response to mutations, high versatility, high safety, and a fast, cost-efficient, and scalable production in a cell-free system. Vaccines for multiple indications can be produced using the same process.

➖ During vaccination the mRNA must be delivered directly into cells, which requires specific injection devices, electroporation, or a carrier molecule. mRNA vaccines exhibit instability and require a cold chain

BETTER MRNA VACCINE DEVELOPMENT

Optimal transcription reaction conditions

The Eppendorf ThermoMixer^® allows easy and precisely controlled up-scaling of the in vitro transcription reactions for mRNA production. The optional ThermoTop further increases temperature homogeneity and prevents condensate formation.

Find the right conditions with fewer PCRs

The in vitro transcription for mRNA vaccines requires the amplification of long, sometimes GC-rich DNA templates. With the Mastercycler^® X50 2D gradient function, up to hundreds of PCR conditions can be checked in one run, saving you time and money.

Safe and consistent culturing of cells

The CellXpert^® C170i offers fast temperature and CO2 recovery (< 5 min/s) and very stable environmental conditions for (e.g) virus host cells as well as reliable contamination prevention (e.g. 180 °C sterilization).

Speed up In Vitro Screening assays

The Eppendorf Xplorer^® enables quick filling of plates using the dispensing mode. When connected to the Pipette Manager, an even quicker operation of the pipette is possible.

Maximize antigen retrieval

The LoBind^® material guarantees maximum sample retrieval for sensitive assays (e.g.) during protein-antigen characterization and lowest contamination risk. LoBind consumables are coating free and therefore, induce minimal risk of subsequent assay interference.

Automate your repetitive, routine tasks

With the epMotion^® you can use a variety of kits e.g. for plasmid isolation. The epMotion has an intuitive drag-and-drop-based software and full consumable flexibility.

Boost mRNA yield and quality

The liquid-free control system of the DASbox^® Mini Bioreactor System ensures fast and precise temperature control of mRNA synthesis reactions. The variable speed pumps of the DASbox ensure accurate addition of reaction components to increase the efficiency of mRNA synthesis.

Smart and safe sample storage

Safe Code Vials enable next level traceability when storing your mRNA at -80°C. Get ID-specific consumable information for comprehensive documentation during your R&D phase. The ACT certified CryoCube freezers ensure energy efficiency and sample safety.

*All products are for Research Use Only (RUO).

DOWNLOADS

Application Note

Breaking Barriers: Endpoint PCR in 15 Minutes or Less

Application Note

Standardized and Water-free Cell Thawing using the Eppendorf ThermoMixer^® C with the Eppendorf SmartBlock™ cryo thaw

White Paper

Digitalization in the Lab − Really a One-Way Towards More Sustainability?

White Paper

How to Develop and Assemble a Sustainable ULT Freezer?

Application Note

E. coli Plasmid DNA Production Using the DASbox® Mini Bioreactor System

Strong growing vaccines: Recombinant protein vaccines

Protein subunit vaccines as for influenza or hepatitis B and C are a proven strategy for decades and still today in the spotlight for pandemic management.

Discover more

Inactivated Vaccine / Live-attenuated vaccine

Traditional vaccines: Inactivated and live-attenuated vaccines

Whole inactivated vaccines, first introduced in 1869 for typhoid, still carry the full repertoire of immunogenic components of the original pathogen.

Discover more

Back to overview

Vous vous apprêtez à quitter ce site.

THE MOST NOVEL VACCINES

BETTER MRNA VACCINE DEVELOPMENT

Optimal transcription reaction conditions

Find the right conditions with fewer PCRs

Safe and consistent culturing of cells

Speed up In Vitro Screening assays

Maximize antigen retrieval

Automate your repetitive, routine tasks

Boost mRNA yield and quality

Smart and safe sample storage

DOWNLOADS

Strong growing vaccines: Recombinant protein vaccines

Traditional vaccines: Inactivated and live-attenuated vaccines